2-Benzo[1,3]dioxol-5-yl-1-methyl-ethylamine

ID: ALA6731

Cas Number: 51497-09-7

PubChem CID: 1614

Max Phase: Phase

Molecular Formula: C10H13NO2

Molecular Weight: 179.22

Molecule Type: Small molecule

Associated Items:

This compound is not in our inventory system

Names and Identifiers

Synonyms: Mda (psychedelic) | Methylene dioxyamphetamine | Tenamfetamine | EA-1299 | SKF-5 | Tenamfetamine|3,4-methylenedioxyamphetamine|4764-17-4|Methylenedioxyamphetamine|3,4-Methylenedioxy-amphetamine|Tenamfetamine [INN]|MDA (pharmaceutical)|1-(1,3-benzodioxol-5-yl)propan-2-amine|1,3-Benzodioxole-5-ethanamine, alpha-methyl-|Love|methylene dioxyamphetamine|EA-1299|BRN 0150196|DEA No. 7400|AI3-24882|alpha-Methyl-1,3-benzodioxole-5-ethanamine|CHEMBL6731|XJZ28FJ27W|ALPHA-METHYL-3,4-(METHYLENEDIOXY)PHENETHYShow More

Canonical SMILES:  CC(N)Cc1ccc2c(c1)OCO2

Standard InChI:  InChI=1S/C10H13NO2/c1-7(11)4-8-2-3-9-10(5-8)13-6-12-9/h2-3,5,7H,4,6,11H2,1H3

Standard InChI Key:  NGBBVGZWCFBOGO-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 13 14  0  0  0  0  0  0  0  0999 V2000
   -2.0458    0.7750    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0458   -0.6792    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3958    1.1875    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3958   -1.1292    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2208    0.0250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8083    1.4875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4292    0.7375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8083   -1.3917    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7000    1.4500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4292   -0.6417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9375   -0.7167    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.9792    0.7000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2125    1.3750    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  1  1  0
  4  2  1  0
  5  3  1  0
  6  1  1  0
  7  6  2  0
  8  2  1  0
  9  7  1  0
 10  7  1  0
 11 12  1  0
 12  9  1  0
 13 12  1  0
  4  5  1  0
  8 10  2  0
M  END

Alternative Forms

  1. Parent:

  2. Alternative Forms:

Associated Targets(Human)

Homo sapiens (32628 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HEK293 (82097 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC6A4 Tclin Serotonin transporter (12625 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SH-SY5Y (11521 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC6A2 Tclin Norepinephrine transporter (10102 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC6A3 Tclin Dopamine transporter (10535 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DG-75 (165 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Whole blood (398 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Slc6a4 Serotonin transporter (6087 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Rattus norvegicus (775804 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Slc6a2 Norepinephrine transporter (2222 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Htr3a Serotonin (5-HT) receptor (353 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Htr2c Serotonin 2c (5-HT2c) receptor (1134 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Htr2b Serotonin 2 (5-HT2) receptor (2078 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Oryctolagus cuniculus (11301 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Htr2b Serotonin 2b (5-HT2b) receptor (321 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Htr2a Serotonin 2a (5-HT2a) receptor (3540 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Slc6a3 Dopamine transporter (6071 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: YesOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 179.22Molecular Weight (Monoisotopic): 179.0946AlogP: 1.31#Rotatable Bonds: 2
Polar Surface Area: 44.48Molecular Species: BASEHBA: 3HBD: 1
#RO5 Violations: HBA (Lipinski): 3HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 10.01CX LogP: 1.43CX LogD: -1.05
Aromatic Rings: 1Heavy Atoms: 13QED Weighted: 0.74Np Likeness Score: 0.28

References

1. Parker MA, Marona-Lewicka D, Kurrasch D, Shulgin AT, Nichols DE..  (1998)  Synthesis and pharmacological evaluation of ring-methylated derivatives of 3,4-(methylenedioxy)amphetamine (MDA).,  41  (6): [PMID:9526575] [10.1021/jm9705925]
2. Domelsmith LN, Eaton TA, Houk KN, Anderson GM, Glennon RA, Shulgin AT, Castagnoli N, Kollman PA..  (1981)  Photoelectron spectra of psychotropic drugs. 6. Relationships between the physical properties and pharmacological actions of amphetamine analogues.,  24  (12): [PMID:7310818] [10.1021/jm00144a009]
3. Nichols DE, Hoffman AJ, Oberlender RA, Jacob P, Shulgin AT..  (1986)  Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class.,  29  (10): [PMID:3761319] [10.1021/jm00160a035]
4. Glennon RA, Liebowitz SM, Anderson GM..  (1980)  Serotonin receptor affinities of psychoactive phenalkylamine analogues.,  23  (3): [PMID:7365744] [10.1021/jm00177a017]
5. Monte AP, Marona-Lewicka D, Cozzi NV, Nichols DE..  (1993)  Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine.,  36  (23): [PMID:8246240] [10.1021/jm00075a027]
6. Clare BW..  (1998)  The frontier orbital phase angles: novel QSAR descriptors for benzene derivatives, applied to phenylalkylamine hallucinogens.,  41  (20): [PMID:9748359] [10.1021/jm980144c]
7. Clare BW..  (1990)  Structure-activity correlations for psychotomimetics. 1. Phenylalkylamines: electronic, volume, and hydrophobicity parameters.,  33  (2): [PMID:2299636] [10.1021/jm00164a036]
8. Glennon RA, Raghupathi R, Bartyzel P, Teitler M, Leonhardt S..  (1992)  Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity.,  35  (4): [PMID:1542100] [10.1021/jm00082a014]
9. Glennon RA, Raghupathi R, Bartyzel P, Teitler M, Leonhardt S..  (1992)  Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity.,  35  (4): [PMID:1542100] [10.1021/jm00082a014]
10. Cloonan SM, Keating JJ, Butler SG, Knox AJ, Jørgensen AM, Peters GH, Rai D, Corrigan D, Lloyd DG, Williams DC, Meegan MJ..  (2009)  Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents.,  44  (12): [PMID:19717215] [10.1016/j.ejmech.2009.07.027]
11. Cloonan SM, Keating JJ, Corrigan D, O'Brien JE, Kavanagh PV, Williams DC, Meegan MJ..  (2010)  Synthesis and in vitro toxicity of 4-MTA, its characteristic clandestine synthesis byproducts and related sulfur substituted alpha-alkylthioamphetamines.,  18  (11): [PMID:20466553] [10.1016/j.bmc.2010.04.022]
12. McNamara YM, Cloonan SM, Knox AJ, Keating JJ, Butler SG, Peters GH, Meegan MJ, Williams DC..  (2011)  Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1-propenes as a new class of anticancer agents.,  19  (3): [PMID:21227702] [10.1016/j.bmc.2010.11.054]
13. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, 
14. Noorizadeh H, Noorizadeh M, Farmany A.  (2012)  Advanced QSRR models of toxicological screening of basic drugs in whole blood by UPLC-TOFMS,  21  (12): [10.1007/s00044-012-9977-1]
15. Arunotayanun W, Dalley JW, Huang XP, Setola V, Treble R, Iversen L, Roth BL, Gibbons S..  (2013)  An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,  23  (11): [PMID:23602445] [10.1016/j.bmcl.2013.03.066]
16. Kier LB, Hall LH..  (1977)  Structure-activity studies on hallucinogenic amphetamines using molecular connectivity.,  20  (12): [PMID:592329] [10.1021/jm00222a019]
17. Nichols DE, Kostuba LJ..  (1979)  Steric effects of substituents on phenethylamine hallucinogens. 3,4-(Methylenedioxy)amphetamine analogues alkylated on the dioxole ring.,  22  (10): [PMID:513074] [10.1021/jm00196a022]
18. Glennon RA, Liebowitz SM, Mack EC..  (1978)  Serotonin receptor binding affinities of several hallucinogenic phenylalkylamine and N,N-dimethyltryptamine analogues.,  21  (8): [PMID:278843] [10.1021/jm00206a022]
19. Glennon RA..  (2017)  The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.,  60  (7): [PMID:28244748] [10.1021/acs.jmedchem.7b00085]
20. Unpublished dataset,